Trazimera Kit
Product Images NDC 0069-0305

Product Visual Gallery

This gallery contains 13 technical images submitted to the FDA as part of the official labeling for Trazimera (NDC 0069-0305). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Pfizer Laboratories Div Pfizer Inc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Figure 1 (Trazimera 01)

A Kaplan-Meier type cumulative incidence curve showing data over approximately 8 years, comparing two treatment groups: AC→T and AC→T+H, in patients starting paclitaxel/trastuzumab. The X-axis represents time in years since treatment initiation, and the Y-axis shows cumulative incidence. A risk table below the graph indicates the number of patients at risk at several time points for both groups.*

FDA Label Image

Figure 2 (Trazimera 02)

A cumulative incidence chart comparing trastuzumab 1-Year treatment to observation only over 24 months from randomization. The x-axis shows time in months, and the y-axis shows cumulative incidence values from 0 to 0.50. Below the x-axis, numbers at risk are provided at multiple time points for each group.*

FDA Label Image

Figure 3 (Trazimera 03)

A Kaplan-Meier curve chart showing cumulative incidence over time (months) for three chemotherapy treatment regimens: AC→T (doxorubicin + cyclophosphamide followed by docetaxel), AC→TH (doxorubicin + cyclophosphamide followed by docetaxel + trastuzumab), and TCH (docetaxel + carboplatin + trastuzumab). The chart includes a risk table indicating the number of patients at risk at different time points up to 36 months.*

FDA Label Image

Figure 4 (Trazimera 04)

A Kaplan-Meier curve chart depicting disease-free survival over 3.5 years comparing two treatment regimens: one with AC to TH (doxorubicin + cyclophosphamide to paclitaxel + trastuzumab) and another with AC to T (doxorubicin + cyclophosphamide to paclitaxel). The y-axis shows the proportion event-free, and the x-axis shows years. The chart shows the number at risk at different time points for both groups.*

FDA Label Image

Figure 5 (Trazimera 05)

A line graph depicting overall survival (years) with the y-axis showing proportion alive. It compares two treatment groups: AC→T (doxorubicin + cyclophosphamide followed by paclitaxel) shown as a solid line, and AC→T + H (same treatment plus trastuzumab) shown as a dashed line. A table below the graph lists the number of patients at risk over time for each group.*

FDA Label Image

Figure 6 (Trazimera 06)

A Kaplan-Meier curve chart illustrating disease-free survival over 5 years with proportions event-free on the y-axis and years on the x-axis. The graph compares three treatment groups involving doxorubicin, cyclophosphamide, docetaxel, trastuzumab, carboplatin, and platinum salt. The chart includes a legend with three line styles representing the different treatment sequences and a table displaying the number of patients at risk at yearly intervals.*

FDA Label Image

Figure 7 (Trazimera 07)

A product-limit survival estimates graph showing survival probability over duration of survival in months, comparing two treatment groups: Fluoropyrimidine plus Cisplatin (group 1) and Fluoropyrimidine plus Cisplatin plus Trastuzumab (group 2). The plot includes censored data points and the number of subjects at risk over time for each group.*

FDA Label Image

Logo (Trazimera 08)

FDA Label Image

Principal Display Panel (420 mg Vial Label)

Label for Trazimera (trastuzumab-qyyp) injection, powder, lyophilized, for solution, with a strength of 420 mg per vial. The label indicates it is Rx only, for intravenous infusion after reconstitution, multiple-dose vial. Manufacturer is Pfizer Ireland Pharmaceuticals, Cork, Ireland. Storage and administration instructions are included on the label.*

FDA Label Image

Principal Display Panel (20 mL Vial Label)

Label for bacteriostatic water for injection, used as a diluent for reconstitution of Trazimera (trastuzumab-qyyp) 150 mg/7.15 mL injection powder. The 20 mL vial contains 1.1% benzyl alcohol with pH 4.5 to 8.0, sterile and nonpyrogenic. Manufactured by Pfizer Ireland Pharmaceuticals and distributed by Pfizer Labs Division of Pfizer Inc.*

FDA Label Image

Principal Display Panel (Kit Carton)

Label for Trazimera 420 mg/vial (trastuzumab-qyyp) injection, powder, lyophilized, for intravenous infusion after reconstitution. The label specifies that it is a multiple-dose vial and is marked Rx only. Manufactured by Pfizer Laboratories Div Pfizer Inc, it includes storage instructions and reconstitution details. The label features the Pfizer Oncology logo and a barcode.*

FDA Label Image

Trazimera 12

Label for Trazimera (trastuzumab-qyyp) injection, powder, lyophilized, for solution, 150 mg per vial. The label indicates it is for intravenous infusion after reconstitution, single-dose vial, manufactured by Pfizer Ireland Pharmaceuticals in Cork, Ireland. Storage instructions and lot/expiration areas are also included on the label.*

FDA Label Image

Trazimera 13

The packaging label for Trazimera 150 mg/vial (trastuzumab-qyyp) is displayed, a lyophilized powder injection for intravenous infusion after reconstitution. The label includes preparation and storage instructions, manufacturer details (Pfizer Ireland Pharmaceuticals, Cork, Ireland), and distribution by Pfizer Labs, New York. The design features Pfizer Oncology branding and barcodes.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.